Vedolizumab: toward a personalized therapy paradigm for people with ulcerative colitis

Robin J Dart, Mark A Samaan, Nick Powell, Peter M Irving

Research output: Contribution to journalReview articlepeer-review

9 Citations (Scopus)


Ulcerative colitis (UC) is a chronic relapsing and remitting inflammatory bowel disease, with a characteristic leukocytic infiltration of the mucosa. Immunosuppression including anti-TNF-α therapy is a mainstay of treatment for many; however, systemic immunosuppression is not universally effective and is associated with potential side effects. The gut-tropic integrin α4β7, which is expressed on leukocytes, mediates migration from the circulation to the intestinal mucosa. Vedolizumab is a monoclonal antibody which blocks the egress of leukocytes via α4β7, preventing accumulation in the mucosa, and attenuating inflammation without systemic immunosuppression. Vedolizumab has been evaluated in UC in a phase III trial, demonstrating efficacy as both an induction and a maintenance agent. In this article, we review the clinical trial data and also explore the growing body of "real-world" effectiveness data, investigating response and remission rates of vedolizumab in clinical practice. In addition, we review the increasing volume of data supporting the reassuring safety profile associated with vedolizumab.

Original languageEnglish
Pages (from-to)57-66
Number of pages10
Publication statusPublished - 2017


Dive into the research topics of 'Vedolizumab: toward a personalized therapy paradigm for people with ulcerative colitis'. Together they form a unique fingerprint.

Cite this